bluebird bio (NASDAQ:BLUE) Trading Up 0.4%

Shares of bluebird bio, Inc. (NASDAQ:BLUE) were up 0.4% on Thursday . The company traded as high as $1.42 and last traded at $1.37. Approximately 1,919,620 shares changed hands during trading, a decline of 80% from the average daily volume of 9,808,183 shares. The stock had previously closed at $1.37.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. HSBC dropped their price target on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research note on Tuesday, March 5th. Bank of America decreased their price target on bluebird bio from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, December 21st. StockNews.com upgraded bluebird bio to a “sell” rating in a research note on Friday, December 8th. Royal Bank of Canada reissued a “sector perform” rating and set a $6.00 target price on shares of bluebird bio in a research note on Wednesday. Finally, Wells Fargo & Company reduced their price target on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $5.87.

bluebird bio Trading Down 6.2 %

The stock has a 50-day moving average price of $1.24 and a two-hundred day moving average price of $2.28. The stock has a market cap of $139.96 million, a price-to-earnings ratio of -1.72 and a beta of 0.75.

Institutional Investors Weigh In On bluebird bio

A number of large investors have recently modified their holdings of the business. US Bancorp DE grew its position in bluebird bio by 885.7% during the 2nd quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 6,749 shares during the last quarter. Raymond James & Associates acquired a new stake in shares of bluebird bio during the first quarter worth $50,000. Stifel Financial Corp acquired a new stake in shares of bluebird bio during the third quarter worth $32,000. Penserra Capital Management LLC purchased a new stake in shares of bluebird bio during the first quarter valued at $53,000. Finally, Aigen Investment Management LP acquired a new position in shares of bluebird bio in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.